Oral GLP-1RA could ‘revolutionise’ obesity management: expert

5 minute read


Associate Professor Sof Andrikopoulos says the drug, currently in clinical development, has the potential to improve affordability and access.


This content is for AHPRA registered professionals only.
Join Now

End of content

No more pages to load

Log In Register ×